| Identification | Back Directory | [Name]
2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide | [CAS]
2815286-02-1 | [Synonyms]
2-[4-[[4-Amino-3-(2-amino-5-benzoxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-1-piperidinyl]-N-hydroxy-5-pyrimidinecarboxamide | [Molecular Formula]
C23H23N11O3 | [MOL File]
2815286-02-1.mol | [Molecular Weight]
501.5 |
| Hazard Information | Back Directory | [Uses]
mTOR/HDAC-IN-1 (Compound 50) is a selective mTOR and HDAC dual inhibitor with IC50 values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an anti-cancer agent[1]. | [IC 50]
mTOR: 0.49 nM (IC50); HDAC1: 0.91 nM (IC50); HDAC6: 86 nM (IC50); HDAC8: 27 nM (IC50) | [References]
[1] Mingming Zhang, et al. Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. Bioorg Med Chem Lett. 2021 Oct 1;49:128286. DOI:10.1016/j.bmcl.2021.128286 |
|
|